BNP Paribas Financial Markets’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $925K | Sell |
665,630
-64,779
| -9% | -$89K | ﹤0.01% | 3192 |
|
|
2025
Q4 | $1.18M | Sell |
730,409
-128,132
| -15% | -$268K | ﹤0.01% | 2994 |
|
|
2025
Q3 | $2.34M | Buy |
858,541
+337,912
| +65% | +$1.12M | ﹤0.01% | 2508 |
|
|
2025
Q2 | $1.9M | Buy |
520,629
+472,855
| +990% | +$1.3M | ﹤0.01% | 2505 |
|
|
2025
Q1 | $91.7K | Buy |
47,774
+13,175
| +38% | +$26.9K | ﹤0.01% | 4067 |
|
|
2024
Q4 | $65.7K | Sell |
34,599
-11,671
| -25% | -$20.3K | ﹤0.01% | 4320 |
|
|
2024
Q3 | $61.1K | Buy |
46,270
+31,137
| +206% | +$41.6K | ﹤0.01% | 3579 |
|
|
2024
Q2 | $15.4K | Buy |
15,133
+14,962
| +8,750% | +$18.5K | ﹤0.01% | 3672 |
|
|
2024
Q1 | $313 | Sell |
171
-8,677
| -98% | -$13.9K | ﹤0.01% | 3924 |
|
|
2023
Q4 | $11K | Hold |
8,848
| – | – | ﹤0.01% | 3704 |
|
|
2023
Q3 | $10.1K | Buy |
8,848
+165
| +2% | +$212 | ﹤0.01% | 3624 |
|
|
2023
Q2 | $7.95K | Hold |
8,683
| – | – | ﹤0.01% | 3642 |
|
|
2023
Q1 | $4.87K | Sell |
8,683
-846
| -9% | -$646 | ﹤0.01% | 3582 |
|
|
2022
Q4 | $5.5K | Sell |
9,529
-15,286
| -62% | -$4.79K | ﹤0.01% | 3660 |
|
|
2022
Q3 | $7.85K | Sell |
24,815
-65,725
| -73% | -$25.8K | ﹤0.01% | 4207 |
|
|
2022
Q2 | $32K | Buy |
90,540
+50,066
| +124% | +$21K | ﹤0.01% | 3646 |
|
|
2022
Q1 | $29.1K | Sell |
40,474
-30,449
| -43% | -$65.1K | ﹤0.01% | 3666 |
|
|
2021
Q4 | $160K | Sell |
70,923
-7,106
| -9% | -$19.4K | ﹤0.01% | 3457 |
|
|
2021
Q3 | $225K | Buy |
78,029
+14,961
| +24% | +$42.7K | ﹤0.01% | 2992 |
|
|
2021
Q2 | $239K | Sell |
63,068
-11,500
| -15% | -$38.7K | ﹤0.01% | 2821 |
|
|
2021
Q1 | $252K | Buy |
74,568
+53,939
| +261% | +$194K | ﹤0.01% | 2927 |
|
|
2020
Q4 | $57.8K | Sell |
20,629
-13,366
| -39% | -$39K | ﹤0.01% | 3491 |
|
|
2020
Q3 | $85.3K | Buy |
33,995
+22,661
| +200% | +$199K | ﹤0.01% | 3203 |
|
|
2020
Q2 | $154K | Sell |
11,334
-35,509
| -76% | -$367K | ﹤0.01% | 2597 |
|
|
2020
Q1 | $355K | Buy |
46,843
+32,891
| +236% | +$256K | ﹤0.01% | 2547 |
|
|
2019
Q4 | $88.2K | Sell |
13,952
-4,822
| -26% | -$22.9K | ﹤0.01% | 3347 |
|
|
2019
Q3 | $73.6K | Buy |
18,774
+8,434
| +82% | +$36.1K | ﹤0.01% | 3280 |
|
|
2019
Q2 | $50K | Sell |
10,340
-8,334
| -45% | -$47.4K | ﹤0.01% | 3416 |
|
|
2019
Q1 | $153K | Buy |
18,674
+13,896
| +291% | +$95.4K | ﹤0.01% | 2849 |
|
|
2018
Q4 | $26.4K | Buy |
4,778
+2,966
| +164% | +$23.2K | ﹤0.01% | 2998 |
|
|
2018
Q3 | $16K | Sell |
1,812
-541
| -23% | -$4.84K | ﹤0.01% | 3507 |
|
|
2018
Q2 | $23.5K | Sell |
2,353
-7,130
| -75% | -$71.4K | ﹤0.01% | 3432 |
|
|
2018
Q1 | $90.4K | Buy |
9,483
+691
| +8% | +$9.67K | ﹤0.01% | 3238 |
|
|
2017
Q4 | $131K | Buy |
8,792
+4,463
| +103% | +$74K | ﹤0.01% | 3167 |
|
|
2017
Q3 | $85.2K | Sell |
4,329
-255
| -6% | -$3.92K | ﹤0.01% | 2872 |
|
|
2017
Q2 | $65.9K | Buy |
4,584
+4,525
| +7,669% | +$57.4K | ﹤0.01% | 3047 |
|
|
2017
Q1 | $543 | Sell |
59
-543
| -90% | -$5.3K | ﹤0.01% | 3833 |
|
|
2016
Q4 | $6.27K | Sell |
602
-1,916
| -76% | -$16.5K | ﹤0.01% | 3628 |
|
|
2016
Q3 | $22.8K | Buy |
2,518
+1,180
| +88% | +$10K | ﹤0.01% | 2819 |
|
|
2016
Q2 | $10K | Buy |
+1,338
| New | +$11.7K | ﹤0.01% | 2913 |
|
|
2016
Q1 | – | Sell |
-5,048
| Closed | -$65.2K | – | 2672 |
|
|
2015
Q4 | $65.2K | Sell |
5,048
-16
| -0.3% | -$163 | ﹤0.01% | 2609 |
|
|
2015
Q3 | $48.9K | Buy |
5,064
+3,036
| +150% | +$27.9K | ﹤0.01% | 2878 |
|
|
2015
Q2 | $20.9K | Buy |
2,028
+1,845
| +1,008% | +$15.7K | ﹤0.01% | 3026 |
|
|
2015
Q1 | $2.03K | Buy |
+183
| New | +$1.95K | ﹤0.01% | 3470 |
|
|
2014
Q4 | – | Sell |
-586
| Closed | -$13K | – | 2023 |
|
|
2014
Q3 | $13K | Buy |
+586
| New | +$13.5K | ﹤0.01% | 3451 |
|
Other funds holding AKBA
VCM
VPM
BNP Paribas Financial Markets's AKBA Position: Q1 2026 in Review
BNP Paribas Financial Markets reduced its Akebia Therapeutics (AKBA) stake by 8.9% in Q1 2026, selling an estimated $89K and leaving 665,630 shares worth $925K. The position accounts for ﹤0.01% of the portfolio, ranked #3192.
BNP Paribas Financial Markets first reported a position in AKBA in Q3 2014 and has held it in 45 quarters since. The position peaked at $2.34M in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- BNP Paribas Financial Markets held 665,630 shares of Akebia Therapeutics worth $925K as of Q1 2026.
- BNP Paribas Financial Markets sold 64,779 Akebia Therapeutics shares in Q1 2026, an estimated $89K.
- Akebia Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #3192 holding.
- BNP Paribas Financial Markets first reported a position in Akebia Therapeutics in Q3 2014 and has held it in 45 quarters since.
- BNP Paribas Financial Markets's Akebia Therapeutics position peaked at $2.34M in Q3 2025.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.